Cure Alzheimer's Fund Cure Alzheimer's Fund

Luisa Quinti, Ph.D.

Instructor in Neurology, Massachusetts General Hospital

Luisa Quinti received her undergraduate degree in Chemistry from the University of Pavia, in Italy and then pursued a Ph.D. in Chemistry at the Manchester Metropolitan University, UK. She moved to Boston, Massachusetts, as post-doctoral fellow and started working at Massachusetts General Hospital as a biochemist. Dr. Quinti is currently an Instructor in the Department of Neurology, working with Prof. Rudolph Tanzi. She has been actively involved in the development of therapeutics for several neurodegenerative diseases since 2005 and is passionate about developing and implementing reliable models of Alzheimer’s disease that can identify novel drug targets and fast-track the search for a cure.

Together with Prof. Doo Yeon Kim, she is translating novel technologies developed in the lab into robust drug-screening platforms to find AD drug candidates that can be readily evaluated for human trials.

Related Research:

Exploring Novel Drug Candidates for Alzheimer’s Disease Through Integrative Pathway Analysis and Validation in 3D Cellular Models Doo Yeon Kim Luisa Quinti 2024-02-01 Validation and Characterization of Compounds Modulating Neuroinflammation and Amyloid Beta Uptake in Microglial Cells Ana Griciuc Luisa Quinti 2023-10-25 Alzheimer’s Disease Drug Discovery and Development Consortium: High-Throughput Drug Screening for Alzheimer’s Disease Using Three-Dimensional Human Neural Culture Systems Doo Yeon Kim Luisa Quinti 2022-02-14 High-Throughput Drug Screening for Alzheimer’s Disease Using Three-Dimensional Human Neural Culture Systems Doo Yeon Kim Luisa Quinti 2020-12-18

Funded Research

These projects were made possible from Cure Alzheimer's Fund support.

Project Description Researchers Funding
Exploring Novel Drug Candidates for Alzheimer’s Disease Through Integrative Pathway Analysis and Validation in 3D Cellular Models 2024

$210,250
Validation and Characterization of Compounds Modulating Neuroinflammation and Amyloid Beta Uptake in Microglial Cells 2023

$201,250
Alzheimer’s Disease Drug Discovery and Development Consortium: High-Throughput Drug Screening for Alzheimer’s Disease Using Three-Dimensional Human Neural Culture Systems 2021, 2022

$461,180
High-Throughput Drug Screening for Alzheimer’s Disease Using Three-Dimensional Human Neural Culture Systems 2020

$230,000

Selected Publications

These published papers resulted from Cure Alzheimer’s Fund support.

Liang, Y., Lee, D. Y. W., Zhen, S., Sun, H., Zhu, B., Liu, J., Lei, D., Lin, C. J., Zhang, S., Jacques, N. A., Quinti, L., Ran, C., Wang, C., Griciuc, A., Choi, S. H., Dai, R. H., Efferth, T., Tanzi, R. E., & Zhang, C. Natural medicine HLXL targets multiple pathways of amyloid-mediated neuroinflammation and immune response in treating alzheimer’s disease, Phytomedicine, May 13, 2022, Read More

Kim, E., Kim, H., Jedrychowski, M. P., Bakiasi, G., Park, J., Kruskop, J., Choi, Y., Kwak, S. S., Quinti, L., Kim, D. Y., Wrann, C. D., Spiegelman, B. M., Tanzi, R. E., & Choi, S. H. Irisin reduces amyloid-β by inducing the release of neprilysin from astrocytes following downregulation of ERK-STAT3 signaling, Neuron, September 8, 2023, Read More

Back to Our Researchers